Toxoplasma gondii (T. gondii) reactivation is one of the fatal complications after hematopoietic stem cell transplantation (HSCT); however, re-infection has not been reported. Here we report a case of mycosis fungoides in which cervical lymphadenopathy developed after HSCT. Initially, recurrent lymphoma was suspected. However, biopsy of the lymph node showed typical histology of toxoplasmosis and serology showed re-infection of T. gondii. Toxoplasmosis needs to be differentiated for cases with lymphoadenopthy after HSCT.
Introduction Toxoplasma gondii (T. gondii) is an opportunistic protozoan, and reactivation of latent disease is believed to be the main cause of symptomatic disease after allogeneic hematopoietic stem cell transplantation (HSCT) (1) . Disseminated disease is associated with considerable morbidity and mortality (2, 3) . Here we report a case of mycosis fungoides in which cervical lymphadenopathy developed due to re-infection of T. gondii after HSCT. Re-biopsy of the lymph node was important to rule out recurrent lymphoma.
Case Report
A 58-year-old woman was followed up for diagnosis of parapsoriasis at a regional dermatology clinic for 9 years. She was referred to our hospital because of rapidly growing painful left inguinal lymphadenopathy and masses in her left thigh. Skin biopsy revealed mycosis fungoides and lymph node biopsy showed infiltration of mature T cell lymphoma.
She received 4 courses of the CHOP regimen, which resulted in refractory disease, and the EPOCH regimen was therefore given as salvage therapy. Since she still had a refractory skin lesion even after 4 courses of the EPOCH regimen, allogeneic HSCT was performed.
The conditioning regimen consisted of Fludarabine, Melphalan and low-dose TBI.
Short-term MTX and Tacrolimus were administered as prophylaxis against GVHD.
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Its causative agent, T. gondii, is a facultatively heteroxenous, polyxenous protozoon that has developed several potential routes of transmission within and between different host species. Transmission to humans may occur via ingestion of infectious oocysts from the environment (usually via soil contaminated with feline feces), via organ transplants, or via tissue cysts in meat from an infected animal or from contaminated fruits, vegetables, or water. However, it is not known which of these routes is more important epidemiologically. It is likely that the major routes of transmission are different in human populations with differences in culture and eating habits (4). The seroprevalence of T. gondii varies markedly among different regions, ranging from 10% to 50-80%. In Japan, the seropositivity for T. gondii in the general population has been reported to be approximately 10-15% (5) . In a chart review in our department, seropositivity of T. gondii was found to be 10.8% (33 seropositive patients in 306 patients), which is almost the same as that in the United Status and lower than that in other countries (6) . When immunocompetent adults are primarily infected with T. gondii, the majority of them are usually asymptomatic. Approximately 10% of patients show symptoms like those of infectious mononucleosis including fever, chills, muscular pain, prominent cervical lymphadenopathy, hepatitis. The most common manifestation is bilateral, symmetrical, and non-tender cervical lymphadenopathy. The lymph nodes are usually smaller than 3 cm in size and non-fluctuant (7) .
In HSCT recipients, toxoplasmosis is a relatively rare complication. The incidence of toxoplasmosis after HSCT was reported to be 0.1-6.0% (4, 5, 8-11), but it is a potentially fatal opportunistic parasitic infection with an estimated mortality rate of 60-90% (12) (13) (14) (15) . In Japan, definite diagnosis of toxoplasmosis after allo-HSCT was reported to be very rare (0.22%) (5) . Most cases of toxoplasmosis occur due to reactivation with organ symptoms, particularly in patients with GVHD and in umbilical cord blood transplant recipients (16, 17) .
The largest scale review showed 356 cases of toxoplasmosis following allo-HSCT (6).
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